KwokHing personal page - To The Moon

KwokHing

KwokHing

No personal profile

1Follow

2Followers

0Topic

0Badge

2022-06-21

K

@TechnicalHunter:2 Ways to Confirm a Market Bottom & 3 Levels to Buy

2022-04-20

Posting for chances

2022-04-19

For easter hunt chance

2022-04-18

Posting for easter egg change

2022-04-17

Posting for easter chance

2022-04-16

Any good stocks to recommend?

2022-04-15

Test test

2022-04-14

Great ariticle, would you like to share it?

@TigerEvents:🏆【GAME】Hunting Eggs for Extra Saving!

2021-07-14

Urm

Apple's potential 'buy now, pay later' plan sends sector shares tumbling

2021-06-21

?? ??

Orphazyme rose more than 6% in premarket trading

2021-04-17

Urm

Sorry, the original content has been removed

2021-04-17

Can consider

Sorry, the original content has been removed

2021-04-17

Can consider

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581737440579845","uuid":"3581737440579845","gmtCreate":1618643416512,"gmtModify":1618654286875,"name":"KwokHing","pinyin":"kwokhing","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":1,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9049293753,"gmtCreate":1655795467872,"gmtModify":1676535706979,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049293753","repostId":"9049202900","repostType":1,"repost":{"id":9049202900,"gmtCreate":1655794295752,"gmtModify":1676535706826,"author":{"id":"3448793367875557","authorId":"3448793367875557","name":"TechnicalHunter","avatar":"https://static.tigerbbs.com/20616c062c392e47ee8fc9107f46437d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3448793367875557","authorIdStr":"3448793367875557"},"themes":[],"title":"2 Ways to Confirm a Market Bottom & 3 Levels to Buy","htmlText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","listText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","text":"When the Market will hit Bottom? 2 Ways to Comfirm & 3 Levels to WatchU.S. stocks and other stock markets fell last week after raising interest rates.The S&P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&P has fallen more than 23% since its January 2022 high. $NASDAQ(.IXIC)$ decreased 4.78%, $DJIA(.DJI)$ declined 4.79%, YTD performance of each are, -24.7%, -17.5% respectively.$S&P/ASX 200(XJO.AU)$ Last week performed the worst week","images":[{"img":"https://community-static.tradeup.com/news/5403fbc4d0d6ccf9f5cc97050aa533e4","width":"1035","height":"201"},{"img":"https://community-static.tradeup.com/news/a3970d0e3842c3b440ced19bb2f56166","width":"664","height":"415"},{"img":"https://community-static.tradeup.com/news/18b0bdfae0727f344fe9d1993ba9e17b","width":"1240","height":"810"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049202900","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088721555,"gmtCreate":1650384858926,"gmtModify":1676534711047,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for chances","listText":"Posting for chances","text":"Posting for chances","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088721555","isVote":1,"tweetType":1,"viewCount":2270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088553009,"gmtCreate":1650368085917,"gmtModify":1676534706244,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"For easter hunt chance","listText":"For easter hunt chance","text":"For easter hunt chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088553009","isVote":1,"tweetType":1,"viewCount":2823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088090246,"gmtCreate":1650287811041,"gmtModify":1676534686938,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter egg change","listText":"Posting for easter egg change","text":"Posting for easter egg change","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088090246","isVote":1,"tweetType":1,"viewCount":3224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081979173,"gmtCreate":1650188135864,"gmtModify":1676534665863,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter chance","listText":"Posting for easter chance","text":"Posting for easter chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081979173","isVote":1,"tweetType":1,"viewCount":2395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9083842898,"gmtCreate":1650097378570,"gmtModify":1676534647348,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Any good stocks to recommend?&nbsp;","listText":"Any good stocks to recommend?&nbsp;","text":"Any good stocks to recommend?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9083842898","isVote":1,"tweetType":1,"viewCount":2631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089442933,"gmtCreate":1650027803960,"gmtModify":1676534631595,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Test test","listText":"Test test","text":"Test test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089442933","isVote":1,"tweetType":1,"viewCount":1957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089921783,"gmtCreate":1649946588253,"gmtModify":1676534612985,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089921783","repostId":"9016476123","repostType":1,"repost":{"id":9016476123,"gmtCreate":1649229403658,"gmtModify":1676534474180,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"🏆【GAME】Hunting Eggs for Extra Saving!","htmlText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","listText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","text":"Tiger has prepared some Easter gifts for you, please click here to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","images":[{"img":"https://community-static.tradeup.com/news/15b435c0d10e0e89ad3e06b7bbd04830","width":"2251","height":"1334"},{"img":"https://community-static.tradeup.com/news/ff9640a9df2f24446e07b7a9b658cb4b","width":"1200","height":"630"},{"img":"https://community-static.tradeup.com/news/795038848b7c7b1d7dda27d92b580946","width":"1656","height":"948"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016476123","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144027308,"gmtCreate":1626255579104,"gmtModify":1703756436600,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/144027308","repostId":"1176184294","repostType":4,"repost":{"id":"1176184294","kind":"news","pubTimestamp":1626254217,"share":"https://ttm.financial/m/news/1176184294?lang=&edition=fundamental","pubTime":"2021-07-14 17:16","market":"us","language":"en","title":"Apple's potential 'buy now, pay later' plan sends sector shares tumbling","url":"https://stock-news.laohu8.com/highlight/detail?id=1176184294","media":"Reuters","summary":" -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.The U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.The prospect of going up against a behemoth like Apple, as well a","content":"<p>(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.</p>\n<p>The U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.</p>\n<p>The prospect of going up against a behemoth like Apple, as well as other entrants including PayPal, was likely to test Australian pure-play BNPL firms that have so far gone unchallenged in a fertile U.S. market.</p>\n<p>Shares of Australia-listed Afterpay, the country’s biggest BNPL provider which derives a big chunk of its revenue from the United States, dived nearly 10% on Wednesday.</p>\n<p>Smaller rivals Zip Co Ltd and Sezzle fell sharply. Nasdaq-listed Affirm Holdings Inc tumbled more than 14% on Tuesday following the Bloomberg report and closed 10.5% lower.</p>\n<p>Apple Pay is a bigger threat than potential offerings from banks or credit companies given its wide reach and superior consumer experience on a mobile website or in-store, a client note by Citi analysts said.</p>\n<p>The BNPL industry has boomed as online shopping picked up pace during the global health crisis, with the number of merchants in the United States adding the repayment option nearly tripling in 2020, according to a McKinsey report.</p>\n<p>In Australia, where the regulation of the fast-growing sector is light and adoption is higher compared to other markets, a Deloitte report said 30% of the consumers in the country have a BNPL account.</p>\n<p>The sector’s fast-paced growth attracted Swedish firm Klarna, which has emerged as a major rival in Australia, and caught the attention of mainstream U.S. companies.</p>\n<p>U.S. payments giant PayPal launched its service in Australia on Wednesday and raised the ante by saying it would do away with late fees, an area that had earned Afterpay close to A$70 million ($52.23 million) in fiscal 2020.</p>\n<p>The Bloomberg report said Apple Pay users would be allowed to split their payments into four interest-free instalments, or across several months with interest - a model similar to rivals Klarna, Afterpay, Zip’s Quadpay and Affirm.</p>\n<p>A Goldman Sachs spokesperson declined to comment, while Apple was not available for comment.</p>\n<p>Afterpay said competition reinforces the significance of the sector and that each BNPL player operates a different model and generate revenue in different ways.</p>\n<p>A Zip spokesman said Apple’s reported move validated the company’s business where it was growing customer numbers despite increased competition.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's potential 'buy now, pay later' plan sends sector shares tumbling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's potential 'buy now, pay later' plan sends sector shares tumbling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic ...</p>\n\n<a href=\"https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","PYPL":"PayPal"},"source_url":"https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176184294","content_text":"(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.\nThe U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.\nThe prospect of going up against a behemoth like Apple, as well as other entrants including PayPal, was likely to test Australian pure-play BNPL firms that have so far gone unchallenged in a fertile U.S. market.\nShares of Australia-listed Afterpay, the country’s biggest BNPL provider which derives a big chunk of its revenue from the United States, dived nearly 10% on Wednesday.\nSmaller rivals Zip Co Ltd and Sezzle fell sharply. Nasdaq-listed Affirm Holdings Inc tumbled more than 14% on Tuesday following the Bloomberg report and closed 10.5% lower.\nApple Pay is a bigger threat than potential offerings from banks or credit companies given its wide reach and superior consumer experience on a mobile website or in-store, a client note by Citi analysts said.\nThe BNPL industry has boomed as online shopping picked up pace during the global health crisis, with the number of merchants in the United States adding the repayment option nearly tripling in 2020, according to a McKinsey report.\nIn Australia, where the regulation of the fast-growing sector is light and adoption is higher compared to other markets, a Deloitte report said 30% of the consumers in the country have a BNPL account.\nThe sector’s fast-paced growth attracted Swedish firm Klarna, which has emerged as a major rival in Australia, and caught the attention of mainstream U.S. companies.\nU.S. payments giant PayPal launched its service in Australia on Wednesday and raised the ante by saying it would do away with late fees, an area that had earned Afterpay close to A$70 million ($52.23 million) in fiscal 2020.\nThe Bloomberg report said Apple Pay users would be allowed to split their payments into four interest-free instalments, or across several months with interest - a model similar to rivals Klarna, Afterpay, Zip’s Quadpay and Affirm.\nA Goldman Sachs spokesperson declined to comment, while Apple was not available for comment.\nAfterpay said competition reinforces the significance of the sector and that each BNPL player operates a different model and generate revenue in different ways.\nA Zip spokesman said Apple’s reported move validated the company’s business where it was growing customer numbers despite increased competition.","news_type":1,"symbols_score_info":{"AAPL":0.9,"PYPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167674161,"gmtCreate":1624267978453,"gmtModify":1703831989964,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"?? ??&nbsp;","listText":"?? ??&nbsp;","text":"?? ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/167674161","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":3842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379994901,"gmtCreate":1618649126403,"gmtModify":1704713823086,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379994901","repostId":"1156411249","repostType":4,"isVote":1,"tweetType":1,"viewCount":1126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379992711,"gmtCreate":1618648961133,"gmtModify":1704713821136,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379992711","repostId":"2127834845","repostType":4,"isVote":1,"tweetType":1,"viewCount":1038,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379996487,"gmtCreate":1618648833649,"gmtModify":1704713819507,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581737440579845","authorIdStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379996487","repostId":"2127834845","repostType":4,"isVote":1,"tweetType":1,"viewCount":821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9088721555,"gmtCreate":1650384858926,"gmtModify":1676534711047,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Posting for chances","listText":"Posting for chances","text":"Posting for chances","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088721555","isVote":1,"tweetType":1,"viewCount":2270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088553009,"gmtCreate":1650368085917,"gmtModify":1676534706244,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"For easter hunt chance","listText":"For easter hunt chance","text":"For easter hunt chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088553009","isVote":1,"tweetType":1,"viewCount":2823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9049293753,"gmtCreate":1655795467872,"gmtModify":1676535706979,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049293753","repostId":"9049202900","repostType":1,"repost":{"id":9049202900,"gmtCreate":1655794295752,"gmtModify":1676535706826,"author":{"id":"3448793367875557","authorId":"3448793367875557","name":"TechnicalHunter","avatar":"https://static.tigerbbs.com/20616c062c392e47ee8fc9107f46437d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3448793367875557","idStr":"3448793367875557"},"themes":[],"title":"2 Ways to Confirm a Market Bottom & 3 Levels to Buy","htmlText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","listText":"When the Market will hit Bottom? <a href=\"https://ttm.financial/TW/9049202900\" target=\"_blank\">2 Ways to Comfirm &amp; 3 Levels to Watch</a>U.S. stocks and other stock markets fell last week after raising interest rates.The S&amp;P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&amp;P has fallen more than 23% since its January 2022 high.&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a>&nbsp;decreased&nbsp;4.78%,&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a>&nbsp;declined&nbsp;4.79%,&nbsp;YTD&nbsp;performance&nbsp;of&nbsp;each&nbsp;are,&nbsp;-24.7%,&nbsp;-17.5%&nbsp;respectively.<a target=\"_blank\" href=\"https://laohu8.com/S/XJO.AU\">$S&amp;P/ASX 200(XJO.AU)$</a> Last week performed the worst week","text":"When the Market will hit Bottom? 2 Ways to Comfirm & 3 Levels to WatchU.S. stocks and other stock markets fell last week after raising interest rates.The S&P 500 officially fell into its 20th bear market in nearly 140 years. As of June 17, the S&P has fallen more than 23% since its January 2022 high. $NASDAQ(.IXIC)$ decreased 4.78%, $DJIA(.DJI)$ declined 4.79%, YTD performance of each are, -24.7%, -17.5% respectively.$S&P/ASX 200(XJO.AU)$ Last week performed the worst week","images":[{"img":"https://community-static.tradeup.com/news/5403fbc4d0d6ccf9f5cc97050aa533e4","width":"1035","height":"201"},{"img":"https://community-static.tradeup.com/news/a3970d0e3842c3b440ced19bb2f56166","width":"664","height":"415"},{"img":"https://community-static.tradeup.com/news/18b0bdfae0727f344fe9d1993ba9e17b","width":"1240","height":"810"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049202900","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088090246,"gmtCreate":1650287811041,"gmtModify":1676534686938,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter egg change","listText":"Posting for easter egg change","text":"Posting for easter egg change","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088090246","isVote":1,"tweetType":1,"viewCount":3224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081979173,"gmtCreate":1650188135864,"gmtModify":1676534665863,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Posting for easter chance","listText":"Posting for easter chance","text":"Posting for easter chance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081979173","isVote":1,"tweetType":1,"viewCount":2395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9083842898,"gmtCreate":1650097378570,"gmtModify":1676534647348,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Any good stocks to recommend?&nbsp;","listText":"Any good stocks to recommend?&nbsp;","text":"Any good stocks to recommend?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9083842898","isVote":1,"tweetType":1,"viewCount":2631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089442933,"gmtCreate":1650027803960,"gmtModify":1676534631595,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Test test","listText":"Test test","text":"Test test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089442933","isVote":1,"tweetType":1,"viewCount":1957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167674161,"gmtCreate":1624267978453,"gmtModify":1703831989964,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"?? ??&nbsp;","listText":"?? ??&nbsp;","text":"?? ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/167674161","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://ttm.financial/m/news/1184501396?lang=&edition=fundamental","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p>\n<p><img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p>\n<p><b>So what</b></p>\n<p>The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p>\n<p>Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p>\n<p>Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p>\n<p><b>Now what</b></p>\n<p>According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p>\n<p>Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p>\n<p>Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":3842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144027308,"gmtCreate":1626255579104,"gmtModify":1703756436600,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/144027308","repostId":"1176184294","repostType":4,"repost":{"id":"1176184294","kind":"news","pubTimestamp":1626254217,"share":"https://ttm.financial/m/news/1176184294?lang=&edition=fundamental","pubTime":"2021-07-14 17:16","market":"us","language":"en","title":"Apple's potential 'buy now, pay later' plan sends sector shares tumbling","url":"https://stock-news.laohu8.com/highlight/detail?id=1176184294","media":"Reuters","summary":" -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.The U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.The prospect of going up against a behemoth like Apple, as well a","content":"<p>(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.</p>\n<p>The U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.</p>\n<p>The prospect of going up against a behemoth like Apple, as well as other entrants including PayPal, was likely to test Australian pure-play BNPL firms that have so far gone unchallenged in a fertile U.S. market.</p>\n<p>Shares of Australia-listed Afterpay, the country’s biggest BNPL provider which derives a big chunk of its revenue from the United States, dived nearly 10% on Wednesday.</p>\n<p>Smaller rivals Zip Co Ltd and Sezzle fell sharply. Nasdaq-listed Affirm Holdings Inc tumbled more than 14% on Tuesday following the Bloomberg report and closed 10.5% lower.</p>\n<p>Apple Pay is a bigger threat than potential offerings from banks or credit companies given its wide reach and superior consumer experience on a mobile website or in-store, a client note by Citi analysts said.</p>\n<p>The BNPL industry has boomed as online shopping picked up pace during the global health crisis, with the number of merchants in the United States adding the repayment option nearly tripling in 2020, according to a McKinsey report.</p>\n<p>In Australia, where the regulation of the fast-growing sector is light and adoption is higher compared to other markets, a Deloitte report said 30% of the consumers in the country have a BNPL account.</p>\n<p>The sector’s fast-paced growth attracted Swedish firm Klarna, which has emerged as a major rival in Australia, and caught the attention of mainstream U.S. companies.</p>\n<p>U.S. payments giant PayPal launched its service in Australia on Wednesday and raised the ante by saying it would do away with late fees, an area that had earned Afterpay close to A$70 million ($52.23 million) in fiscal 2020.</p>\n<p>The Bloomberg report said Apple Pay users would be allowed to split their payments into four interest-free instalments, or across several months with interest - a model similar to rivals Klarna, Afterpay, Zip’s Quadpay and Affirm.</p>\n<p>A Goldman Sachs spokesperson declined to comment, while Apple was not available for comment.</p>\n<p>Afterpay said competition reinforces the significance of the sector and that each BNPL player operates a different model and generate revenue in different ways.</p>\n<p>A Zip spokesman said Apple’s reported move validated the company’s business where it was growing customer numbers despite increased competition.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's potential 'buy now, pay later' plan sends sector shares tumbling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's potential 'buy now, pay later' plan sends sector shares tumbling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-14 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic ...</p>\n\n<a href=\"https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","PYPL":"PayPal"},"source_url":"https://www.reuters.com/article/apple-pay-goldman-sachs/update-4-apples-potential-buy-now-pay-later-plan-sends-sector-shares-tumbling-idUSL4N2OP3RO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176184294","content_text":"(Reuters) -A report that Apple Inc is working on a service to let users pay for purchases in instalments dragged down shares in the ‘buy now, pay later’ sector, which has thrived during the pandemic as online shoppers look for easier repayment options.\nThe U.S. tech giant will use Goldman Sachs, its partner since 2019 for the Apple Card credit card, as the lender for the loans, Bloomberg News reported, citing people familiar with the matter.\nThe prospect of going up against a behemoth like Apple, as well as other entrants including PayPal, was likely to test Australian pure-play BNPL firms that have so far gone unchallenged in a fertile U.S. market.\nShares of Australia-listed Afterpay, the country’s biggest BNPL provider which derives a big chunk of its revenue from the United States, dived nearly 10% on Wednesday.\nSmaller rivals Zip Co Ltd and Sezzle fell sharply. Nasdaq-listed Affirm Holdings Inc tumbled more than 14% on Tuesday following the Bloomberg report and closed 10.5% lower.\nApple Pay is a bigger threat than potential offerings from banks or credit companies given its wide reach and superior consumer experience on a mobile website or in-store, a client note by Citi analysts said.\nThe BNPL industry has boomed as online shopping picked up pace during the global health crisis, with the number of merchants in the United States adding the repayment option nearly tripling in 2020, according to a McKinsey report.\nIn Australia, where the regulation of the fast-growing sector is light and adoption is higher compared to other markets, a Deloitte report said 30% of the consumers in the country have a BNPL account.\nThe sector’s fast-paced growth attracted Swedish firm Klarna, which has emerged as a major rival in Australia, and caught the attention of mainstream U.S. companies.\nU.S. payments giant PayPal launched its service in Australia on Wednesday and raised the ante by saying it would do away with late fees, an area that had earned Afterpay close to A$70 million ($52.23 million) in fiscal 2020.\nThe Bloomberg report said Apple Pay users would be allowed to split their payments into four interest-free instalments, or across several months with interest - a model similar to rivals Klarna, Afterpay, Zip’s Quadpay and Affirm.\nA Goldman Sachs spokesperson declined to comment, while Apple was not available for comment.\nAfterpay said competition reinforces the significance of the sector and that each BNPL player operates a different model and generate revenue in different ways.\nA Zip spokesman said Apple’s reported move validated the company’s business where it was growing customer numbers despite increased competition.","news_type":1,"symbols_score_info":{"AAPL":0.9,"PYPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379994901,"gmtCreate":1618649126403,"gmtModify":1704713823086,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Urm","listText":"Urm","text":"Urm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379994901","repostId":"1156411249","repostType":4,"isVote":1,"tweetType":1,"viewCount":1126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9089921783,"gmtCreate":1649946588253,"gmtModify":1676534612985,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089921783","repostId":"9016476123","repostType":1,"repost":{"id":9016476123,"gmtCreate":1649229403658,"gmtModify":1676534474180,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"🏆【GAME】Hunting Eggs for Extra Saving!","htmlText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","listText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","text":"Tiger has prepared some Easter gifts for you, please click here to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","images":[{"img":"https://community-static.tradeup.com/news/15b435c0d10e0e89ad3e06b7bbd04830","width":"2251","height":"1334"},{"img":"https://community-static.tradeup.com/news/ff9640a9df2f24446e07b7a9b658cb4b","width":"1200","height":"630"},{"img":"https://community-static.tradeup.com/news/795038848b7c7b1d7dda27d92b580946","width":"1656","height":"948"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016476123","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379992711,"gmtCreate":1618648961133,"gmtModify":1704713821136,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379992711","repostId":"2127834845","repostType":4,"isVote":1,"tweetType":1,"viewCount":1038,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379996487,"gmtCreate":1618648833649,"gmtModify":1704713819507,"author":{"id":"3581737440579845","authorId":"3581737440579845","name":"KwokHing","avatar":"https://static.tigerbbs.com/d80ee49f7842f3db214b610908d8374d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581737440579845","idStr":"3581737440579845"},"themes":[],"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379996487","repostId":"2127834845","repostType":4,"isVote":1,"tweetType":1,"viewCount":821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}